Aurora Investment Counsel’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-14,835
Closed -$1.98M 113
2023
Q4
$1.98M Buy
14,835
+314
+2% +$41.3K 1.29% 14
2023
Q3
$1.77M Buy
14,521
+341
+2% +$45.4K 1.17% 19
2023
Q2
$1.99M Sell
14,180
-49
-0.3% -$6.75K 1.28% 11
2023
Q1
$2.01M Sell
14,229
-58
-0.4% -$8.3K 1.32% 10
2022
Q4
$2.24M Sell
14,287
-173
-1% -$24.9K 1.54% 3
2022
Q3
$1.77M Buy
14,460
+87
+0.6% +$11.5K 1.35% 10
2022
Q2
$1.91M Buy
14,373
+68
+0.5% +$9.27K 1.38% 5
2022
Q1
$1.96M Buy
14,305
+276
+2% +$38.5K 1.25% 6
2021
Q4
$2.43M Buy
14,029
+1,543
+12% +$235K 1.44% 2
2021
Q3
$1.81M Buy
12,486
+8
+0.1% +$1.17K 1.26% 8
2021
Q2
$1.65M Buy
+12,478
New +$1.63M 1.15% 20

Other funds holding DGX

Aurora Investment Counsel's DGX Position: Q1 2024 in Review

Aurora Investment Counsel sold out of Quest Diagnostics (DGX) in Q1 2024, closing a stake of 14,835 shares — an estimated $1.98M sold.

Aurora Investment Counsel first reported a position in DGX in Q2 2021 and held it in 11 quarters. The position peaked at $2.43M in Q4 2021. 819 funds tracked by Wall St. Rank hold DGX as of Q1 2024.

  • Aurora Investment Counsel reported no remaining Quest Diagnostics position as of Q1 2024 after selling out during the quarter.
  • Aurora Investment Counsel sold 14,835 Quest Diagnostics shares in Q1 2024, an estimated $1.98M.
  • Aurora Investment Counsel first reported a position in Quest Diagnostics in Q2 2021 and held it in 11 quarters.
  • Aurora Investment Counsel's Quest Diagnostics position peaked at $2.43M in Q4 2021.
  • 819 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2024.

Based on Aurora Investment Counsel's 13F filing for Q1 2024, filed 4 Jun 2024.